Pharmaceutical News

Celexa and Lexapro Fraud Lawsuit Gets Green Light from Appeals Court

The First Circuit Court of Appeals has reversed a district court’s dismissal of lawsuits filed by a mother and a trade union health care fund who alleged Forest Laboratories, Inc. (now part of Allergan) fraudulently induced them to buy Celexa and Lexapro for use in children and adolescents despite evidence the [...]

By |2019-04-19T10:43:53-07:00March 13th, 2019|Celexa News, Lexapro News, Pharma News|

Brent Wisner Named One of America’s Most Influential Trial Lawyers

Jan. 22, 2019 – Miami, Florida - - The National Law Journal and the Trial Lawyer Magazine named Baum, Hedlund, Aristei & Goldman attorney and partner, R. Brent Wisner, one of America’s 50 Most Influential Trial Lawyers for his success over the past year. The outstanding civil plaintiff and criminal [...]

Baum Hedlund Aristei & Goldman Recognized as 2018 Elite Trial Lawyers

Dec. 5, 2018 – Los Angeles, California - - The National Law Journal has recognized the law firm of Baum, Hedlund, Aristei & Goldman in its 2018 Elite Trial Lawyers list for pharmaceutical litigation based on the firm’s work in a high-profile case against drug manufacturer GlaxoSmithKline. Baum, Hedlund, Aristei [...]

Baum, Hedlund, Aristei & Goldman a Finalist for 2018 Elite Trial Lawyers

July 26, 2018 – LOS ANGELES, CA - - The National Law Journal announced today that the law firm of Baum, Hedlund, Aristei & Goldman is a finalist for the 2018 Elite Trial Lawyers. The Elite Trial Lawyers honors the country’s top plaintiffs’ lawyers and their firms for outstanding work [...]

Law360 Names BHAG Attorney Brent Wisner Titan of the Plaintiffs Bar

May 7, 2018 – Los Angeles, California - - Legal news media company Law360 named Baum, Hedlund, Aristei & Goldman attorney R. Brent Wisner a Titan of the Plaintiffs Bar. Wisner was one of ten attorneys Law360 profiled for earning significant legal victories in 2017. According to Law360, the attorneys [...]

By |2018-06-06T12:45:52-07:00May 7th, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Widow Maintains GSK Liable for Suicide in Paxil Lawsuit Appeal

March 1, 2018 – Chicago, Illinois — The widow of a Chicago lawyer who took his own life while taking a generic version of Paxil (paroxetine), a GlaxoSmithKline (GSK) antidepressant, told a federal appeals court that a jury’s verdict holding GSK liable for her husband’s suicide should stand. In the [...]

By |2018-04-11T10:51:38-07:00March 1st, 2018|Blog, Paxil News, Pharma News, Press Releases, R. Brent Wisner|

Researchers Seek Retraction of MD-18 Celexa Study

Feb. 23, 2018 – Los Angeles, California – A group of researchers sent a letter this week to Dr. Robert Freedman, Editor of the American Journal of Psychiatry, calling for the retraction of a Celexa study the researchers claim is rife with “serious misrepresentations.” The study, known as the MD-18 ‘Wagner’ [...]

Baum Hedlund Urges DOJ to Reopen Investigation re Celexa / Lexapro Clinical Trials

Boston, Massachusetts – February 8, 2018 - - The law firm of Baum, Hedlund, Aristei & Goldman has sent a letter and memorandum to the U.S. Attorney’s Office (USAO) for the District of Massachusetts calling for the reopening of its investigation and prosecution of Forest Laboratories Inc. and its subsidiary, [...]

Acthar Class Action Accuses Mallinckrodt of Inflating Price 85,000%

Los Angeles, California - - A class action lawsuit filed on behalf of numerous Medicare Advantage Organizations (MAOs) accuses pharmaceutical manufacturer Mallinckrodt (MNK) of engaging in a scheme to drastically inflate the price and reduce competition for its drug H.P. Acthar Gel (Acthar), a drug primarily prescribed for infants with [...]

Judge Refuses GlaxoSmithKline Motion for New Paxil Suicide Trial

Chicago, Illinois -- A federal judge has entered judgment against GlaxoSmithKline (“GSK”) affirming the April 20, 2017 jury verdict in favor of Wendy Dolin who alleged her husband’s 2010 suicide was the result of side effects he suffered while taking generic Paxil (paroxetine). Following the jury’s $3,000,000 verdict in Dolin’s [...]

By |2017-09-15T16:16:20-07:00September 14th, 2017|Blog, Paxil News, Pharma News, Press Releases, Michael L. Baum, R. Brent Wisner|